Abstract The transcription factor SOX9 is regarded as a crucial player in pancreas development, both maintaining progenitors and later being required for beta cell differentiation. However, very little is known about the possible involvement of other SOX family members in such processes. In this issue, the work of Xu et al (DOI: 10.1007/s00125-015-3507-x) shines a spotlight on SOX4, revealing this factor to be a major player in the beta cell program. Using conditional inactivation in mice, they show that SOX4 shares some functions in progenitors with SOX9, but also plays a distinct role at a later stage of development, during the maturation of endocrine cells. This information is timely as this final maturation process is currently the most challenging to reproduce in vitro when coaxing pluripotent stem cells to convert into beta cells.
Abstract The transcription factor SOX9 is regarded as a crucial player in pancreas development, both maintaining progenitors and later being required for beta cell differentiation. However, very little is known about the possible involvement of other SOX family members in such processes. In this issue, the work of Xu et al (DOI: 10.1007/s00125-015-3507-x) shines a spotlight on SOX4, revealing this factor to be a major player in the beta cell program. Using conditional inactivation in mice, they show that SOX4 shares some functions in progenitors with SOX9, but also plays a distinct role at a later stage of development, during the maturation of endocrine cells. This information is timely as this final maturation process is currently the most challenging to reproduce in vitro when coaxing pluripotent stem cells to convert into beta cells. There are two major medical reasons to study the development of the pancreas and its endocrine cells. The first is that conditions and diseases that only manifest postnatally or even in the adult sometimes stem from embryonic developmental defects. In this regard, diabetes is certainly no exception. While fetal programming of diabetes and neonatal diabetes are obvious examples [1, 2] , this may extend to other forms of type 1 or type 2 diabetes. The second reason for studying pancreatic development is that understanding how beta cells are formed in the embryo provides a roadmap to produce them in vitro from human pluripotent stem cells (hPSCs). While the ability to produce beta cells in potentially unlimited numbers holds great allure as a prospective diabetes therapy, in vitro-generated beta cells are significant in their own right as models of human beta cells, be that normal or genetically impaired [3] . Beta cells, like the other specialised cells in the pancreas, arise from self-renewing progenitors that either differentiate into the various pancreatic cell types or divide to yield new progenitors, so expanding the progenitor pool to enable continued growth of the organ. Over the course of development, the ability of progenitors to form different specialised pancreatic cell types (their 'potency') progressively narrows. This restriction of potency is a stepwise process, the primogenitor being the 'multipotent' pancreatic progenitor that is capable of generating all of the specialised cells of the pancreas, but not those of other organs (Fig. 1 ). This cell type is transient and current evidence suggests that it only exists at the earliest stages of pancreas development (embryonic day [E]8.5-E13.5 in mice) [4] . These multipotent progenitors then give rise to either specialised acinar-specific progenitors or socalled 'bipotent' progenitors that yield the ductal cells and endocrine cells of the islets (Fig. 1 ). The latter, in turn, arise via an endocrine progenitor intermediate, derived from pancreatic or bipotent progenitors (Fig. 1) . Such endocrine progenitors are transient and generally non-proliferative, each differentiating into a single endocrine cell.
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In this issue of Diabetologia, Xu et al [5] demonstrate that the transcription factor (TF) sex-determining region Y-related high mobility group box 4 (SOX4) controls the generation of beta cells at two distinct developmental steps: first, the production of neurogenin 3 (NEUROG3)-expressing endocrine progenitors and then, second, their subsequent differentiation into endocrine cells. This role is somewhat unexpected in that it differs from that of another SOX-family protein, SOX9, which plays a major role in the maintenance and expansion of multipotent pancreatic progenitors. While also expressed in such progenitors, SOX4 is apparently not required for their maintenance in mice. In spite of these differences, SOX9 and SOX4 both promote endocrine differentiation in progenitors by directly upregulating Neurog3 expression via its promoter [6] [7] [8] . The relatively modest reduction (30%) in endocrine progenitor numbers upon Sox4 inactivation in pancreas progenitors implies functional redundancy between SOX4 and possibly other family members. The often parallel roles played by members of the same subgroup [9] make intra-subgroup redundancy more likely. Thus, it is plausible that absence of SOX4 is partially compensated by, for example, SOX11, which, like SOX4, is a subgroup C factor ostensibly expressed in developing endocrine cells [10] and has been shown to be upregulated in Sox4-null pancreases [11] . Given their colocalisation in a subpopulation of progenitors, it is also possible that SOX9 and SOX4 are redundant in initiating endocrine commitment. This is, however, their only functional redundancy, as SOX4 is expressed in nascent endocrine cells and promotes their maturation into beta cells, a function not shared with SOX9. This feature places SOX4 in the limelight, as the final maturation of beta cells is currently the most limiting step in the hPSC-to-beta cell pipeline, in spite of considerable recent advances made in this endeavour [12, 13] . Xu et al [5] show that if Sox4 is deleted in Neurog3-expressing endocrine progenitors in mice, the endocrine cells, instead of differentiating, accumulate as an apparently generic secretory cell expressing synaptophysin and chromogranin A. While the exact identity and differentiation status of these partially differentiated cells remains unclear, what is clear is that the expression of crucial endocrine TFs acting atop a hierarchy of functional genes is greatly reduced. This is the case, for example, for NeuroD and Pax4: their expression is positively and synergistically regulated by direct co-binding of NEUROG3 and SOX4. This feature is a characteristic of SOX proteins, which usually exert their transcriptional activity by forming complexes with other transcription factors, implying that SOX binding sites in target genes are in the vicinity of a binding site for the partner protein. However, it remains to be demonstrated whether SOX4 and NEUROG3 TFs physically interact to promote the transactivation of NeuroD and Pax4 (or other genes) during endocrine differentiation. Importantly, the dual function of SOX4 revealed by Xu et al [5] , namely, the promotion of endocrine commitment and subsequent maturation of nascent endocrine cells, could potentially be explained by substitution of SOX4 partners. This would result in a dramatic change in the repertoire of target genes. One can speculate that the SOX4-TF complex activates the transcription of another transcription factor, which then functions as a novel partner. Alternatively, SOX factor exchange (e.g. SOX4 for SOX9), while the partner remains the same, could be conceived as well. Both mechanisms have been demonstrated to promote the stepwise progression of developmental processes in other paradigms (see [14] for a review). Xu et al now possess the tools to further decipher the SOX4-associated transcriptional machinery governing endocrine development. This partial differentiation phenotype, characterised by islet cells with generic hallmarks of endocrine cells but lacking hormones, is reminiscent of that seen upon loss of the endocrine TFs insulinoma-associated 1 (INSM1), ISL LIM homeobox 1 (ISL1) or regulatory factor X, 6 (RFX6) [15] [16] [17] [18] . These factors are likely to synergise in a TF network promoting beta cell maturation. Sox4 has not yet been scrutinised in the quality control of hPSC-to-beta cell differentiation protocols and appears to deserve more attention. Whether SOX4 plays a similarly significant role in beta cell development in humans as in the mouse remains to be seen.
While a previous report in zebrafish [19] already implicated a crucial role for Sox4 in endocrine differentiation, its role in this species appears to be restricted to glucagon-producing cells. However, this may be due to the fact that this study did not examine the role of Sox4 in the generation of the late beta cells, which most resemble those of mammals. Alternatively, the divergence in Sox4-deficient pancreatic phenotypes between mouse and zebrafish may reflect discrepancies in the transcriptional programs governing endocrine differentiation in these two models.
As is the case for several pancreatic TFs (e.g. pancreatic and duodenal homeobox 1 [PDX1], RFX6, neurogenic differentiation 1 [NEUROD1], NK6 homeobox 1 [NKX6.1], ISL1), SOX4 appears to be an essential factor both for beta cell development and postnatal function. The latter role is supported by the study of two independent autosomaldominant N-ethyl-N-nitrosourea (ENU)-induced mutations in the SOX4 high mobility group box, leading to glucose intolerance and impaired insulin secretion in mice [20] . However, it cannot be completely excluded that such mice carry additional ENU mutations that might contribute to this phenotype. Thus, the generation and examination of mice lacking Sox4 specifically in beta cells will now enable the confirmation and further dissection of the role of SOX4 in beta cell function.
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